<span item_type="fundamental" item_id="df900f723874fa95ea53f1c54413e5bc" counter_id="ST/US/BFRIW" env="prod"></span><span item_type="announcement" item_id="648251836484491137" env="prod"></span><p>Revenue: As of FY2026 Q1, the actual value is USD 10.08 M.</p><p>EPS: As of FY2026 Q1, the actual value is USD -0.41.</p><p>EBIT: As of FY2026 Q1, the actual value is USD -4.195 M.</p><p></p><h3>Revenue</h3><ul><li>Total revenues for Biofrontera Inc. were $10.1 million in Q1 2026, a 17% increase compared to $8.6 million in Q1 2025. This growth was primarily driven by approximately 16% growth in Ameluz units sold and a price increase implemented in Q4 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1858685/000149315226022875/ex99-1.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li><strong>Gross Margin</strong>: Gross profit margin was approximately 80% in Q1 2026, an 18 percentage point increase from approximately 62% in Q1 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1858685/000149315226022875/ex99-1.htm"></span></li><li><strong>Operating Loss</strong>: Operating loss was - $4.3 million in Q1 2026, an improvement from - $4.5 million in Q1 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1858685/000149315226022875/ex99-1.htm"></span></li><li><strong>Net Loss</strong>: The net loss for Q1 2026 was - $4.8 million, compared to a net loss of - $4.2 million for the prior-year quarter.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1858685/000149315226022875/ex99-1.htm"></span></li><li><strong>Adjusted EBITDA</strong>: Adjusted EBITDA improved to - $3.6 million in Q1 2026 from - $4.4 million in Q1 2025, an improvement of approximately $0.8 million.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1858685/000149315226022875/ex99-1.htm"></span></li><li><strong>Adjusted EBITDA Margin</strong>: The Adjusted EBITDA margin improved to -35.3% from -51.0% in the prior-year quarter.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1858685/000149315226022875/ex99-1.htm"></span></li></ul><h3>Operating Costs</h3><ul><li>Total operating expenses were $14.4 million for Q1 2026, up from $13.1 million for Q1 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1858685/000149315226022875/ex99-1.htm"></span></li><li>Cost of revenues, related party, decreased by approximately 40% year-over-year, from $3,075 thousand in Q1 2025 to $1,831 thousand in Q1 2026.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1858685/000149315226022875/ex99-1.htm"></span></li><li>Selling, general and administrative expenses increased to $11.0 million in Q1 2026 from $8.7 million in Q1 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1858685/000149315226022875/ex99-1.htm"></span></li><li>Research and development expenses decreased to $0.9 million in Q1 2026 from $1.2 million in Q1 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1858685/000149315226022875/ex99-1.htm"></span></li><li>Patent remediation expense was $392 thousand in Q1 2026, compared to $0 in Q1 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1858685/000149315226022875/ex99-1.htm"></span></li></ul><h3>Cash Flow</h3><ul><li>Cash flows used in operating activities were - $70 thousand in Q1 2026, a significant improvement from - $4,117 thousand in Q1 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1858685/000149315226022875/ex99-1.htm"></span></li><li>Cash flows used in investing activities were - $5 thousand in Q1 2026, compared to - $3 thousand in Q1 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1858685/000149315226022875/ex99-1.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li>Ameluz units sold increased by approximately 16% year-over-year.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1858685/000149315226022875/ex99-1.htm"></span></li><li>Biofrontera Inc. recognized $1.2 million in earnout expense during Q1 2026.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1858685/000149315226022875/ex99-1.htm"></span></li></ul><h3>Outlook/Guidance</h3><p>Biofrontera Inc. is focused on achieving sustained profitability and cash-flow breakeven while building a foundation for medium to long-term growth. The company anticipates multiple near-term catalysts, including a PDUFA date for sBCC in September 2026, positive Phase 3 results for AK, and encouraging Phase 2b data in acne, to expand the commercial opportunity for the Ameluz platform.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1858685/000149315226022875/ex99-1.htm"></span></p>

BIOFRONTERA INC C/WTS 27/10/2026 (TO PUR COM) | 8-K: FY2026 Q1 Revenue: USD 10.08 M